10-Q: Tevogen Bio Holdings Reports Q1 2024 Results, Cites Going Concern Uncertainty Despite Net Income

Tevogen Bio Holdings reported a net income of $11.3 million for Q1 2024, primarily due to a change in the fair value of convertible promissory notes, but faces substantial doubt about its ability to continue as a going concern.

Summary

• Tevogen Bio Holdings Inc. reported a net income of $11.3 million for the first quarter of 2024, a significant shift from a net loss of $30.8 million in the same period of 2023.
• The company's Q1 2024 net income was primarily driven by a $48.5 million gain from the change in fair value of convertible promissory notes, which was offset by $7.5 million in merger transaction costs and a $29.5 million loss from operations.
• Operating expenses totaled $29.5 million, with research and development accounting for $20.8 million and general and administrative expenses at $8.7 million.
• The company's cash balance stood at $1.3 million as of March 31, 2024, and it has an accumulated deficit of $88.4 million.
• Tevogen Bio has raised $2 million from the sale of Series A Preferred Stock and $1.2 million from the sale of Series A-1 Preferred Stock.
• Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months due to insufficient cash to fund operations.
• The company is exploring various strategies to secure additional funding, including private placements, licensing agreements, and public offerings.
• The company completed a reverse merger on February 14, 2024, with Tevogen Bio Inc. becoming a wholly-owned subsidiary of Tevogen Bio Holdings Inc.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While the company reports a net income for the quarter, this is largely due to accounting adjustments and not operational success. The significant concern about the company's ability to continue as a going concern, coupled with the need for substantial additional funding, creates a negative outlook. The positive clinical trial results are overshadowed by the financial instability.

Positives

• The company achieved a net income of $11.3 million in Q1 2024, a significant improvement from the net loss in the same period last year.
• The company successfully completed a reverse merger, which could provide strategic advantages.
• Tevogen Bio has raised $3.2 million through the sale of preferred stock, providing some additional capital.
• The company's lead product candidate, TVGN 489, has completed a Phase 1 proof-of-concept trial with positive results.

Negatives

• The company has an accumulated deficit of $88.4 million and a low cash balance of $1.3 million.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• Operating expenses, particularly research and development, have increased significantly.
• The company has not generated any revenue to date and is dependent on external funding.
• The company is in default of its obligations on notes payable of $1,651,000.

Risks

• The company's ability to continue as a going concern is uncertain due to insufficient cash reserves.
• The company is dependent on raising additional capital, which may not be available on acceptable terms or at all.
• The company's research and development efforts may not be successful, and product candidates may not obtain regulatory approval.
• The company faces risks associated with intellectual property protection and competition.
• The company has a limited operating history and is subject to the risks associated with any specialty biotechnology company.
• The company may fail to effectively remediate its material weakness and develop and maintain effective internal controls.

Future Outlook

The company anticipates needing additional capital to fund operations and is exploring various financing options, including a potential line of credit and private placement. The company expects to incur significant expenses related to expanding research and development, building manufacturing infrastructure, and developing its commercialization organization. The company does not expect to generate product revenue until it obtains marketing approval for and successfully commercializes TVGN 489 or another product candidate.

Management Comments

• Management believes that cash of $1,317,900 as of March 31, 2024, and $2,000,000 received for the sale of Series A-1 Preferred Stock subsequent to March 31, 2024, is not sufficient to sustain planned operations for 12 months from the issuance date of these unaudited consolidated financial statements.
• Management is currently evaluating different strategies to obtain the additional funding for future operations for subsequent years.
• Management has concluded that substantial doubt exists about its ability to continue as a going concern for one year from the date that the unaudited consolidated financial statements are issued.

Industry Context

Tevogen Bio operates in the competitive biotechnology industry, focusing on innovative T-cell therapies. The company's approach to developing off-the-shelf, precision T-cell therapies for infectious diseases, cancers, and neurological disorders aligns with the broader industry trend towards personalized medicine and advanced immunotherapies. The company's focus on allogeneic therapies, which are intended to be infused in patients other than the original donor, is a key differentiator in the market.

Comparison to Industry Standards

• Tevogen Bio's focus on allogeneic T-cell therapies is comparable to companies like Allogene Therapeutics and Atara Biotherapeutics, which are also developing off-the-shelf cell therapies.
• The company's ExacTcell platform, which aims to develop single HLA-restricted CTL therapies, is similar to the approach taken by companies like Adaptimmune, which focuses on engineered T-cell receptors.
• The company's lead product candidate, TVGN 489, is targeting COVID-19, a space where several companies are developing treatments and vaccines, including Pfizer, Moderna, and Regeneron.
• Tevogen Bio's financial situation, with a significant accumulated deficit and reliance on external funding, is not uncommon for clinical-stage biotechnology companies, many of which face similar challenges in securing capital and achieving profitability.
• The company's research and development expenses are in line with other companies in the clinical-stage biotechnology sector, which typically invest heavily in research and development activities.

Related Party Transactions

• The company incurred $2,000,000 in fees to the Sponsor for advisory services, with $250,000 payable in cash, $250,000 offset against amounts due from the Sponsor, and the remainder paid with the issuance of 150,000 shares of common stock.
• The Sponsor owes the company $158,819 to cover working capital expenses.
• The company issued 40,000 Performance-Based RSUs to the wife of the company's chair and chief executive officer and 20,000 Performance-Based RSUs to a company controlled by the daughter of the company's chief financial officer.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern uncertainty and need for additional funding.
• Employees may be impacted by potential cost-cutting measures or restructuring if the company faces financial difficulties.
• Customers and patients may be affected by delays in product development or commercialization if the company cannot secure sufficient funding.
• Suppliers and creditors may face increased risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company plans to launch a pivotal trial of TVGN 489 in COVID-19 patients with B cell malignancies.
• The company is in preclinical development for treatment and prevention of Long COVID.
• The company anticipates entering into a definitive agreement for a line of credit during the quarter ending June 30, 2024.
• The company will continue to explore various strategies to secure additional funding.

Key Dates

Keywords

Tevogen Bio, Immunotherapy, CD8+ T lymphocytes, T cell therapies, Infectious diseases, Cancer, Neurological disorders, ExacTcell, TVGN 489, COVID-19, Reverse merger, Clinical trials, Biotechnology, Going concern, Preferred stock, Warrants